Animal models of ulcerative colitis and their application in drug research

Drug Design, Development and Therapy

Volumn 7, Issue , 2013, Pages 1341-1356

  Low, Daren ^a   Nguyen, Deanna D ^a,b   Mizoguchi, Emiko ^a,b  

^a Gastrointestinal Unit   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Emerging therapy; Inflammatory bowel disease; Preclinical trials

Indexed keywords

ACETIC ACID; ALOE VERA EXTRACT; ANDROGRAPHIS PANICULATA EXTRACT; BOSWELLIA SERRATA EXTRACT; BROMELAIN; BUTYRIC ACID; CHAMOMILE; CURCUMIN; DEXAMETHASONE; DEXTRAN SULFATE; GLYCYRRHIZA EXTRACT; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INTERLEUKIN 2; INTERLEUKIN 7; IRRITANT AGENT; ISPAGULA; MESALAZINE; OXAZOLONE; PLACEBO; PLANT EXTRACT; SALAZOSULFAPYRIDINE; STEROID; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; WISKOTT ALDRICH SYNDROME PROTEIN;

ADHERENT INVASIVE ESCHERICHIA COLI; APPENDECTOMY; BACTERIAL COLONIZATION; BACTERIAL VIRULENCE; CAENORHABDITIS ELEGANS; CELL MIGRATION; CELL PROLIFERATION; COMPARATIVE STUDY; CONSTIPATION; CROHN DISEASE; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE MODEL; DROSOPHILA; DRUG DESIGN; DRUG EFFICACY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; ENTERITIS; ENZYME INHIBITION; ESCHERICHIA COLI; EXPERIMENTAL ANIMAL; EXTRACHROMOSOMAL INHERITANCE; FECES MICROFLORA; FLATULENCE; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENETIC ANALYSIS; GENETIC RISK; GENETIC VARIABILITY; GENOME IMPRINTING; HUMAN; IL-7 TG MOUSE; IMMUNOCOMPETENT CELL; INTESTINE EPITHELIUM CELL; KNOCKOUT MOUSE; NAUSEA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PROGENY; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALMONELLA; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; THERAPY WITH HELMINTHS; TRANSGENIC MOUSE; ULCERATIVE COLITIS; ZEBRA FISH;

EMERGING THERAPY; INFLAMMATORY BOWEL DISEASE; PRECLINICAL TRIALS;

ANIMALS; COLITIS, ULCERATIVE; DISEASE MODELS, ANIMAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HUMANS; MOLECULAR TARGETED THERAPY;

EID: 84887803390     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: 10.2147/DDDT.S40107     Document Type: Review

References (123)

1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46-54 e42; quiz e30.
2. Loftus EV Jr, Sandborn WJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31(1):1-20.
3. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17(7):1603-1609.
4. Akolkar PN, Gulwani-Akolkar B, Heresbach D, et al. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am J Gastroenterol. 1997;92(12):2241-2244.
5. Fransen K, Mitrovic M, van Diemen CC, et al. Limited evidence for parent-of-origin effects in inflammatory bowel disease associated loci. PLoS One. 2012;7(9):e45287.
6. Anderson CA, Boucher G, Lees CW, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet. 2011;43(3):246-252.
7. Lewis JD, Aberra FN, Lichtenstein GR, Bilker WB, Brensinger C, Strom BL. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004;126(3):665-673.
8. Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81(11):1462-1471.
9. Bergeron V, Grondin V, Rajca S, et al. Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease. Inflamm Bowel Dis. 2012;18(6):1101-1111.
10. Denson LA, Long MD, McGovern DP, et al. Challenges in IBD research: update on progress and prioritization of the CCFA's research agenda. Inflamm Bowel Dis. 2013;19(4):677-682.
11. Kawada M, Arihiro A, Mizoguchi E. Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol. 2007;13(42):5581-5593.
12. Mizoguchi A. Animal models of inflammatory bowel disease. In: Conn PM, ed. Progress in Molecular Biology and Translational Science. Vol 105. San Diego, CA: Academic Press; 2012.
13. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med. 1998;188(10):1929-1939.
14. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity. 2002;17(5):629-638.
15. Ikeda M, Takeshima F, Isomoto H, et al. Simvastatin attenuates trinitrobenzene sulfonic acid-induced colitis, but not oxazalone-induced colitis. Dig Dis Sci. 2008;53(7):1869-1875.
16. Galitovskiy V, Qian J, Chernyavsky AI, et al. Cytokine-induced alterations of alpha7 nicotinic receptor in colonic CD4 T cells mediate dichotomous response to nicotine in murine models of Th1/Th17-versus Th2-mediated colitis. J Immunol. 2011;187(5):2677-2687.
17. MacPherson BR, Pfeiffer CJ. Experimental production of diffuse colitis in rats. Digestion. 1978;17(2):135-150.
18. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterology. 1995;109(4): 1344-1367.
19. Cetinkaya A, Bulbuloglu E, Kurutas EB, Ciralik H, Kantarceken B, Buyukbese MA. Beneficial effects of N-acetylcysteine on acetic acid-induced colitis in rats. Tohoku J Exp Med. 2005;206(2):131-139.
20. Kuralay F, Yildiz C, Ozutemiz O, et al. Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. J Toxicol Environ Health A. 2003;66(2):169-179.
21. Yoshida N, Yoshikawa T, Yamaguchi T, et al. A novel water-soluble vitamin E derivative protects against experimental colitis in rats. Antioxid Redox Signal. 1999;1(4):555-562.
22. Tahan G, Gramignoli R, Marongiu F, et al. Melatonin expresses powerful anti-inflammatory and antioxidant activities resulting in complete improvement of acetic-acid-induced colitis in rats. Dig Dis Sci. 2011;56(3):715-720.
23. Mann BJ, Burkholder BV, Lockhart LA. Protection in a gerbil model of amebiasis by oral immunization with Salmonella expressing the galactose/N-acetyl D-galactosamine inhibitable lectin of Entamoeba histolytica. Vaccine. 1997;15(6-7):659-663.
24. Mizoguchi E. Chitinase 3-like-1 exacerbates intestinal inflammation by enhancing bacterial adhesion and invasion in colonic epithelial cells. Gastroenterology. 2006;130(2):398-411.
25. Boudeau J, Glasser AL, Masseret E, Joly B, Darfeuille-Michaud A. Invasive ability of an Escherichia coli strain isolated from the ileal mucosa of a patient with Crohn's disease. Infect Immun. 1999;67(9): 4499-4509.
26. Jensen SR, Fink LN, Nielsen OH, Brynskov J, Brix S. Ex vivo intestinal adhesion of Escherichia coli LF82 in Crohn's disease. Microb Pathog. 2011;51(6):426-431.
27. Low D, Tran HT, Lee IA, et al. Chitin-binding domains of Escherichia coli chiA mediate interactions with intestinal epithelial cells in mice with colitis. Gastroenterology. 2013;145(3):602-612.
28. Nagatani K, Wang S, Llado V, et al. Chitin microparticles for the control of intestinal inflammation. Inflamm Bowel Dis. 2012;18(9): 1698-1710.
29. Ingrassia I, Leplingard A, Darfeuille-Michaud A. Lactobacillus casei DN-114 001 inhibits the ability of adherent-invasive Escherichia coli isolated from Crohn's disease patients to adhere to and to invade intestinal epithelial cells. Appl Environ Microbiol. 2005;71(6):2880-2887.
30. Drouet M, Vignal C, Singer E, et al. AIEC colonization and pathogenicity: influence of previous antibiotic treatment and preexisting inflammation. Inflamm Bowel Dis. 2012;18(10):1923-1931.
31. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest. 1995;95(6):2945-2953.
32. Watanabe M, Watanabe N, Iwao Y, et al. The serum factor from patients with ulcerative colitis that induces T cell proliferation in the mouse thymus is interleukin-7. J Clin Immunol. 1997;17(4):282-292.
33. Shinohara T, Nemoto Y, Kanai T, et al. Upregulated IL-7 receptor alpha expression on colitogenic memory CD4+ T cells may participate in the development and persistence of chronic colitis. J Immunol. 2011;186(4):2623-2632.
34. Yamazaki M, Yajima T, Tanabe M, et al. Mucosal T cells expressing high levels of IL-7 receptor are potential targets for treatment of chronic colitis. J Immunol. 2003;171(3):1556-1563.
35. Willis CR, Seamons A, Maxwell J, et al. Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis. J Inflamm (Lond). 2012;9(1):39.
36. Watanabe M, Ueno Y, Yajima T, et al. Interleukin 7 transgenic mice develop chronic colitis with decreased interleukin 7 protein accumulation in the colonic mucosa. J Exp Med. 1998;187(3):389-402.
37. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75(2):274-282.
38. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol. 1997;150(1):91-97.
39. Shimomura Y, Mizoguchi E, Sugimoto K, et al. Regulatory role of B-1 B cells in chronic colitis. Int Immunol. 2008;20(6):729-737.
40. Nishiyori A, Nagakura Y, Ichikawa K. Piroxicam accelerates development of colitis in T-cell receptor alpha chain-deficient mice. Eur J Pharmacol. 2009;615(1-3):241-245.
41. Iijima H, Takahashi I, Kishi D, et al. Alteration of interleukin 4 production results in the inhibition of T helper type 2 cell-dominated inflammatory bowel disease in T cell receptor alpha chain-deficient mice. J Exp Med. 1999;190(5):607-615.
42. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med. 1997;186(10):1749-1756.
43. Sheikh SZ, Hegazi RA, Kobayashi T, et al. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol. 2011;186(9):5506-5513.
44. Hsieh KH, Chang MH, Lee CY, Wang CY. Wiskott-Aldrich syndrome and inflammatory bowel disease. Ann Allergy. 1988;60(5):429-431.
45. Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111(5 Pt 1): e622-e627.
46. Snapper SB, Rosen FS, Mizoguchi E, et al. Wiskott-Aldrich syndrome protein-deficient mice reveal a role for WASP in T but not B cell activation. Immunity. 1998;9(1):81-91.
47. Nguyen DD, Maillard MH, Cotta-de-Almeida V, et al. Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology. 2007;133(4): 1188-1197.
48. Nguyen DD, Wurbel MA, Goettel JA, et al. Wiskott-Aldrich syndrome protein deficiency in innate immune cells leads to mucosal immune dysregulation and colitis in mice. Gastroenterology. 2012;143(3): 719-729.
49. Klein C, Nguyen D, Liu CH, et al. Gene therapy for Wiskott-Aldrich syndrome: rescue of T-cell signaling and amelioration of colitis upon transplantation of retrovirally transduced hematopoietic stem cells in mice. Blood. 2003;101(6):2159-2166.
50. Tuin A, Poelstra K, de Jager-Krikken A, et al. Role of alkaline phosphatase in colitis in man and rats. Gut. 2009;58(3):379-387.
51. Ramasamy S, Nguyen DD, Eston MA, et al. Intestinal alkaline phosphatase has beneficial effects in mouse models of chronic colitis. Inflamm Bowel Dis. 2011;17(2):532-542.
52. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol. 1998;161(10):5733-5744.
53. Tanner SM, Staley EM, Lorenz RG. Altered generation of induced regulatory T cells in the FVB. mdr1a-/-mouse model of colitis. Mucosal Immunol. 2013;6(2):309-323.
54. Staley EM, Dimmitt RA, Schoeb TR, Tanner SM, Lorenz RG. Critical role for P-glycoprotein expression in hematopoietic cells in the FVB. Mdr1a(-/-) model of colitis. J Pediatr Gastroenterol Nutr. 2011;53(6): 666-673.
55. Nones K, Dommels YE, Martell S, et al. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br J Nutr. 2009;101(2):169-181.
56. Annese V, Valvano MR, Palmieri O, Latiano A, Bossa F, Andriulli A. Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis. World J Gastroenterol. 2006;12(23):3636-3644.
57. Langmann T, Moehle C, Mauerer R, et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology. 2004;127(1):26-40.
58. Saksena S, Goyal S, Raheja G, et al. Upregulation of P-glycoprotein by probiotics in intestinal epithelial cells and in the dextran sulfate sodium model of colitis in mice. Am J Physiol Gastrointest Liver Physiol. 2011;300(6):G1115-G1123.
59. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 1993;75(2):253-261.
60. Cruickshank SM, English NR, Felsburg PJ, Carding SR. Characterization of colonic dendritic cells in normal and colitic mice. World J Gastroenterol. 2005;11(40):6338-6347.
61. Waidmann M, Bechtold O, Frick JS, et al. Bacteroides vulgatus protects against Escherichia coli-induced colitis in gnotobiotic interleukin-2-deficient mice. Gastroenterology. 2003;125(1):162-177.
62. Muller M, Fink K, Geisel J, et al. Intestinal colonization of IL-2 deficient mice with non-colitogenic B. vulgatus prevents DC maturation and T-cell polarization. PLoS One. 2008;3(6):e2376.
63. Contractor NV, Bassiri H, Reya T, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol. 1998;160(1):385-394.
64. Ludviksson BR, Strober W, Nishikomori R, Hasan SK, Ehrhardt RO. Administration of mAb against alpha E beta 7 prevents and ameliorates immunization-induced colitis in IL-2-/-mice. J Immunol. 1999;162(8): 4975-4982.
65. Varilek GW, Yang F, Lee EY, et al. Green tea polyphenol extract attenuates inflammation in interleukin-2-deficient mice, a model of autoimmunity. J Nutr. 2001;131(7):2034-2039.
66. Rudolph U, Finegold MJ, Rich SS, et al. Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. Nat Genet. 1995;10(2):143-150.
67. Hornquist CE, Lu X, Rogers-Fani PM, et al. G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines. J Immunol. 1997;158(3):1068-1077.
68. Bjursten M, Willen R, Hultgren Hornquist E. Transfer of colitis by Galphai2-deficient T lymphocytes: impact of subpopulations and tissue origin. Inflamm Bowel Dis. 2005;11(11):997-1005.
69. Dalwadi H, Wei B, Schrage M, et al. B cell developmental requirement for the G alpha i2 gene. J Immunol. 2003;170(4):1707-1715.
70. Ohman L, Willen R, Hultgren OH, Hultgren Hornquist E. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice. Clin Exp Immunol. 2005;141(1):37-46.
71. Fritsch Fredin M, Vidal A, Utkovic H, et al. The application and relevance of ex vivo culture systems for assessment of IBD treatment in murine models of colitis. Pharmacol Res. 2008;58(3-4): 222-231.
72. Lin J, Hackam DJ. Worms, flies and four-legged friends: the applicability of biological models to the understanding of intestinal inflammatory diseases. Dis Model Mech. 2011;4(4):447-456.
73. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol. 1997;151(1):97-110.
74. Podolsky DK, Lobb R, King N, et al. Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody. J Clin Invest. 1993;92(1):372-380.
75. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology. 1996;111(5): 1373-1380.
76. Picarella D, Hurlbut P, Rottman J, Shi X, Butcher E, Ringler DJ. Monoclonal antibodies specific for beta 7 integrin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) reduce inflammation in the colon of scid mice reconstituted with CD45RBhigh CD4+ T cells. J Immunol. 1997;158(5):2099-2106.
77. Neurath MF. New targets for mucosal healing and therapy in inflammatory bowel diseases. Mucosal Immunol. In press 2013.
78. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353(18): 1912-1925.
79. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE trial. Gastroenterology. 2007;132(5):1672-1683.
80. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699-710.
81. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut. 2013;62(8):1122-1130.
82. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut. 2011;60(8):1068-1075.
83. Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology. 1998;114(6):1133-1142.
84. Yacyshyn BR, Chey WY, Goff J, et al. Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. Gut. 2002;51(1):30-36.
85. Miner PB Jr, Wedel MK, Xia S, Baker BF. Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial. Aliment Pharmacol Ther. 2006;23(10):1403-1413.
86. Coskun M, Salem M, Pedersen J, Nielsen OH. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease. Pharmacol Res. 2013;76C:1-8.
87. Durant L, Watford WT, Ramos HL, et al. Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity. 2010;32(5):605-615.
88. Uckun FM, Tibbles H, Ozer Z, Qazi S, Vassilev A. Anti-inflammatory activity profile of JANEX-1 in preclinical animal models. Bioorg Med Chem. 2008;16(3):1287-1298.
89. Sandborn WJ, Ghosh S, Panes J, et al. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012;367(7): 616-624.
90. Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand J Gastroenterol. 1987;22(8):1009-1024.
91. Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy and protection against ulcerative colitis. N Engl J Med. 2001;344(11): 808-814.
92. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med. 1996;184(2):707-715.
93. Krieglstein CF, Cerwinka WH, Laroux FS, et al. Role of appendix and spleen in experimental colitis. J Surg Res. 2001;101(2):166-175.
94. Farkas SA, Hornung M, Sattler C, et al. Preferential migration of CD62L cells into the appendix in mice with experimental chronic colitis. Eur Surg Res. 2005;37(2):115-122.
95. Blum AM, Hang L, Setiawan T, et al. Heligmosomoides polygyrus bakeri induces tolerogenic dendritic cells that block colitis and prevent antigen-specific gut T cell responses. J Immunol. 2012;189(5): 2512-2520.
96. Leung JM, Loke P. A role for IL-22 in the relationship between intestinal helminths, gut microbiota and mucosal immunity. Int J Parasitol. 2013;43(3-4):253-257.
97. Ferreira I, Smyth D, Gaze S, et al. Hookworm excretory/secretory products induce interleukin-4 (IL-4)+ IL-10+ CD4+ T cell responses and suppress pathology in a mouse model of colitis. Infect Immun. 2013;81(6):2104-2111.
98. Cantacessi C, Young ND, Nejsum P, et al. The transcriptome of Trichuris suis: first molecular insights into a parasite with curative properties for key immune diseases of humans. PLoS One. 2011;6(8):e23590.
99. Du L, Tang H, Ma Z, et al. The protective effect of the recombinant 53-kDa protein of Trichinella spiralis on experimental colitis in mice. Dig Dis Sci. 2011;56(10):2810-2817.
100. Bager P, Vinkel Hansen A, Wohlfahrt J, Melbye M. Helminth infection does not reduce risk for chronic inflammatory disease in a population-based cohort study. Gastroenterology. 2012;142(1):55-62.
101. Wang A, Fernando M, Leung G, Phan V, Smyth D, McKay DM. Exacerbation of oxazolone colitis by infection with the helminth Hymenolepis diminuta: involvement of IL-5 and eosinophils. Am J Pathol. 2010;177(6):2850-2859.
102. Wang LJ, Cao Y, Shi HN. Helminth infections and intestinal inflammation. World J Gastroenterol. 2008;14(33):5125-5132.
103. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut. 2010;59(12): 1662-1669.
104. Srivastava AS, Feng Z, Mishra R, Malhotra R, Kim HS, Carrier E. Embryonic stem cells ameliorate piroxicam-induced colitis in IL10-/-KO mice. Biochem Biophys Res Commun. 2007;361(4):953-959.
105. Zhou Q, Price DD, Dreher KL, et al. Localized colonic stem cell transplantation enhances tissue regeneration in murine colitis. J Cell Mol Med. 2012;16(8):1900-1915.
106. Hayashi Y, Tsuji S, Tsujii M, et al. The transdifferentiation of bone-marrow-derived cells in colonic mucosal regeneration after dextran-sulfate-sodium-induced colitis in mice. Pharmacology. 2007;80(4): 193-199.
107. Godoi DF, Cardoso CR, Silva MJ, et al. Reappraisal of total body irradiation followed by bone marrow transplantation as a therapy for inflammatory bowel disease. Immunobiology. 2013;218(3):317-324.
108. He XW, He XS, Lian L, Wu XJ, Lan P. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci. 2012;57(12):3136-3144.
109. Akiyama K, Chen C, Wang D, et al. Mesenchymal-stem-cell-induced immunoregulation involves Fas-ligand-/Fas-mediated T cell apoptosis. Cell Stem Cell. 2012;10(5):544-555.
110. Tanaka F, Tominaga K, Ochi M, et al. Exogenous administration of mesenchymal stem cells ameliorates dextran sulfate sodium-induced colitis via anti-inflammatory action in damaged tissue in rats. Life Sci. 2008;83(23-24):771-779.
111. Hayashi Y, Tsuji S, Tsujii M, et al. Topical implantation of mesenchymal stem cells has beneficial effects on healing of experimental colitis in rats. J Pharmacol Exp Ther. 2008;326(2):523-531.
112. Claes IJ, De Keersmaecker SC, Vanderleyden J, Lebeer S. Lessons from probiotic-host interaction studies in murine models of experimental colitis. Mol Nutr Food Res. 2011;55(10):1441-1453.
113. Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. Lancet. 1989;1(8630):164.
114. Couturier-Maillard A, Secher T, Rehman A, et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest. 2013;123(2):700-711.
115. Kahn SA, Vachon A, Rodriquez D, et al. Patient perceptions of fecal microbiota transplantation for ulcerative colitis. Inflamm Bowel Dis. 2013;19(7):1506-1513.
116. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38(8):854-863.
117. Ke F, Yadav PK, Ju LZ. Herbal medicine in the treatment of ulcerative colitis. Saudi J Gastroenterol. 2012;18(1):3-10.
118. Langmead L, Feakins RM, Goldthorpe S, et al. Randomized, double-blind, placebo-controlled trial of oral aloe vera gel for active ulcerative colitis. Aliment Pharmacol Ther. 2004;19(7):739-747.
119. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002;37(4):444-449.
120. Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis-a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011;33(2):194-202.
121. Langhorst J, Varnhagen I, Schneider SB, et al. Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis: a double-blind, double-dummy study. Aliment Pharmacol Ther. 2013;38(5):490-500.
122. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006;4(12):1502-1506.
123. Michelsen KS, Wong MH, Ko B, Thomas LS, Dhall D, Targan SR. HMPL-004 (Andrographis paniculata extract) prevents development of murine colitis by inhibiting T-cell proliferation and TH1/TH17 responses. Inflamm Bowel Dis. 2013;19(1):151-164.